Promega Introduces New Mass Spec Reagents, IdeS Protease and Human and Yeast Protein Extracts
Promega Corporation announces the launch of new products for scientists working with mass spectrometry. The IdeS Protease enables fast, easy, high performance digestion of immunoglobulin, while the Human and Yeast Protein Extracts provide a test material for optimizing mass spec sample preparation. The new products add to the company’s existing range of proteases and services to improve mass spec sample prep workflows.
IdeS Protease is a recombinant, engineered version of the immunoglobulin-degrading enzyme from Streptococcus pyogenes. It is a highly specific protease that slices Immunoglobulin G (IgG) at a single, targeted site, offering 100% digestion in 30 minutes with no optimization. IdeS can be used to characterize therapeutic antibody candidates using LC/MS, and contains a histidine tag for easy removal. The versatile Promega IdeS enzyme cuts IgGs from a range of species, as well as Fc-fusion proteins.
The new yeast and human protein extracts are designed specifically for mass spectrometry applications. Available in either predigested, cleaned form for immediate use in LC/MS analysis or intact, undigested form to provide a test material for optimizing mass spec protein sample preparation, the extracts provide clean, consistent, quantified, model system samples for LC/MS method development and instrument monitoring. The yeast extracts are beneficial for users who prefer working with a relatively compact and well-studied proteome, whereas the human extract, with large dynamic range, provides the opportunity to work with complex proteomes. The new products are: MS Compatible Yeast Protein Extract, Digest; MS Compatible Human Protein Extract, Digest; MS Compatible Yeast Protein Extract, Intact; and MS Compatible Human Protein Extract, Intact.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...